Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. [electronic resource]
Producer: 20170116Description: 428-38 p. digitalISSN:- 1878-7479
- Administration, Oral
- Adult
- Amides
- Anti-Inflammatory Agents -- administration & dosage
- Cytokines -- blood
- Disease Progression
- Double-Blind Method
- Ethanolamines -- administration & dosage
- Female
- Humans
- Interferon beta-1a -- adverse effects
- Interferon-gamma -- blood
- Interleukin-17 -- blood
- Male
- Multiple Sclerosis, Relapsing-Remitting -- drug therapy
- Palmitic Acids -- administration & dosage
- Skin -- drug effects
- Tumor Necrosis Factor-alpha -- blood
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.